

Additional File 1.

Inclusion of “progressed patients” in analysis population

The current analyses included “progressed patients,” defined as those meeting the general study inclusion/exclusion criteria as well as the following additional eligibility criteria:

- Diagnosed with tumor, nodes, metastasis (TNM) stage I, II, or IIIA non-small cell lung cancer (NSCLC) and received systemic anticancer therapy (SACT) alone as initial treatment
 - o If the initial treatment was SACT alone, then that was captured as the patient’s first-line treatment and any subsequent therapy was captured as second-line treatment
- Diagnosed with TNM stage I, II, or IIIA NSCLC and received one of the following therapies as initial treatment and then received a subsequent SACT regimen:
 - o Surgery + adjuvant SACT
 - o Surgery + adjuvant radiotherapy and SACT
 - o Neoadjuvant SACT + surgery
 - o Neoadjuvant radiotherapy and SACT + surgery
 - o Radiotherapy followed by SACT
 - o SACT followed by radiotherapy
 - o Chemoradiotherapy

For these patients, the subsequent SACT regimen was captured as the patient’s first-line treatment and any subsequent therapy as second-line treatment

Of note, treatment with SACT as described above was used as a proxy for progression to advanced disease (stage IIIB or IV) in “progressed patients”; no confirmatory restaging data were available.